Conference Call with Alkem Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Alkem Laboratories announced Q3FY25 results Total Revenue from Operations was Rs 33,743 million, with YoY growth of 1.5%. India sales were Rs 23,649 million, with YoY growth of 5.9%. International sales were Rs 9,605 million, with YoY de-growth of 6.2%. Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 7,594 million, resulting in an EBITDA margin of 22.5% vs. 21.3% in Q3FY24. EBITDA increased by 7.3% YoY. R&D; expenses for the quarter were Rs 1,312 million, or 3.9% of total revenue from operations, compared to Rs 1,111 million in Q3FY24 at 3.3% of total revenue from operations. Profit before tax (PBT) before exceptional item was Rs 7,311 million, a growth of 3.5% compared to Rs 7,062 million in Q3FY24. Net Profit (after Minority Interest) was Rs 6,258 million, YoY growth of 5.2%. As per IQVIA (SSA) data, for Q3FY25, the company registered a growth of 6.0% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 7.2%. Vikas Gupta, CEO, Alkem, said: “We are pleased to share that the actions we have taken to improve profitability continue to deliver positive results. By concentrating on higher-margin offerings, better aligning with market needs, and implementing cost-saving strategies to reduce inefficiencies, we are seeing growth in our EBITDA margins. Within the domestic market, our focus is on expanding the presence of our flagship brands and strategically enhancing our portfolio. Looking ahead, we are confident that these initiatives will continue to drive sustainable growth and strengthen our market position.” Result PDF
